| CNTMF Stock | | | USD 0.11 0.02 18.28% |
Insider
Robert Beasley is CEO Director of Cansortium
| Phone | 305 902 2720 |
| Web | https://www.getfluent.com |
Cansortium Management Efficiency
The company has return on total asset
(ROA) of
0.021 % which means that it generated a profit of $0.021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.2825) %, meaning that it generated substantial loss on money invested by shareholders. Cansortium's management efficiency ratios could be used to measure how well Cansortium manages its routine affairs as well as how well it operates its assets and liabilities.
Cansortium has accumulated 53.67
M in total debt with debt to equity ratio
(D/E) of 1.89, which is about average as compared to similar companies. Cansortium has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Cansortium until it has trouble settling it off, either with new capital or with free cash flow. So, Cansortium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cansortium sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cansortium to invest in growth at high rates of return. When we think about Cansortium's use of debt, we should always consider it together with cash and equity.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida. Cansortium operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. Cansortium [CNTMF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Cansortium Leadership Team
Elected by the shareholders, the Cansortium's board of directors comprises two types of representatives: Cansortium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cansortium. The board's role is to monitor Cansortium's management team and ensure that shareholders' interests are well served. Cansortium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cansortium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samantha Hymes, Ex Operations | |
| Jennifer McCaffertyFernandez, Chief Officer | |
| William Smith, Ex Chairman | |
| Patricia Fonseca, Ex Officer | |
| Jeffrey Reath, Consultant | |
| Todd Buchman, Chief Sec | |
| Victor Bindi, Director Sales | |
| Liora Boudin, Co CFO | |
| Samantha Senne, Ex Operations | |
| Robert Beasley, CEO Director | |
Cansortium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cansortium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Cansortium OTC Stock
Cansortium financial ratios help investors to determine whether Cansortium OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansortium with respect to the benefits of owning Cansortium security.